Complement Membrane Attack Complex (Membrane Attack Complex)

Subscribe to Selected New Research on Complement Membrane Attack Complex

520 relevant articles (4 outcomes, 42 trials/studies) found for this Bio-Agent

Description: A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC.

Also Known As:

Membrane Attack Complex; C 5b-9; C5b-8-poly-C9; C5b-9; Cytolytic Terminal Complement Complex; Terminal Complement Complex; C5b 8 poly C9; Complement Complex C5b 9; Complement Complex, Terminal; Complex, Terminal Complement; Complement Complex C5b-9

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Blood Proteins: 3862

Immunoproteins: 30

Complement System Proteins: 17483

Complement Membrane Attack Complex: 520

SC5b-9 protein complex: 4

Experts

1.	Niculescu, Florin: 5 articles (01/2006 - 12/2003)
2.	Rus, Horea: 5 articles (01/2006 - 12/2003)
3.	Niculescu, Teodora: 3 articles (10/2005 - 12/2003)
4.	Leontsini, Maria: 2 articles (01/2008 - 01/2002)
5.	Alexopoulos, Efstathios: 2 articles (01/2008 - 01/2002)
6.	Kochs, Matthias: 2 articles (01/2007 - 08/2002)
7.	Hombach, Vinzenz: 2 articles (01/2007 - 08/2002)
8.	Torzewski, Jan: 2 articles (01/2007 - 08/2002)
9.	Zwaka, Thomas P: 2 articles (01/2007 - 08/2002)
10.	Höher, Martin: 2 articles (01/2007 - 08/2002)

Related Diseases

1.	Membranous Glomerulonephritis (Membranous Nephropathy) 01/01/1993 - "In passive Heymann nephritis when disease activity was monitored by urinary C5b-9 excretion, C3c was cleared in parallel with return of urine C5b-9 excretion to normal values. " 07/01/2003 - "Clinical correlates of serial urinary membrane attack complex estimates in patients with idiopathic membranous nephropathy." 01/01/2002 - "BACKGROUND: Cellular immune responses and C5b-9 seem to play an important role in the pathogenesis and progression of idiopathic membranous nephropathy (IMN). " 01/01/2002 - "C5b-9 and adhesion molecules in human idiopathic membranous nephropathy." 04/01/2000 - "(2) Patients with membranous nephropathy showed a unique finding, i.e., isolated increase of membrane attack complex excretion. " Order ALL the reference details at left...
2.	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/01/1998 - "This study investigated whether increased plasma levels of terminal complement complex (SC5b-9) or split products correlate with disease activity and clinical manifestations in Brazilian systemic lupus erythematosus (SLE) patients. " 11/01/1987 - "Terminal complement complex in plasma from patients with systemic lupus erythematosus and other glomerular diseases." 02/04/1982 - "Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus." 07/01/1982 - "Immunopathology of the membrane attack complex in systemic lupus erythematosus nephritis." 12/01/1981 - "Renal localization of the membrane attack complex in systemic lupus erythematosus nephritis." Order ALL the reference details at left...
3.	Inflammation 12/01/2004 - "Complement activation with formation of biologically potent mediators like C5a and the terminal C5b-9 complex (TCC) contributes essentially to development of inflammation and tissue damage in a number of autoimmune and inflammatory conditions. " 12/01/2004 - "As markers of inflammation, the major histocompatibility complex (MHC) class I and class II and the membrane attack complex (MAC) were analysed. " 03/01/2003 - "Membrane attack complex formation in deficient membrane bound CD59 may also exacerbate synovial cell injury and inflammation." 04/01/2001 - "These findings indicate that complement activation and membrane assembly of sublytic C5b-9 play an important role in inflammation by promoting cell proliferation and by rescuing apoptotic cells." 05/01/2000 - "Thus, these findings imply that MAC on the fungal surface may represent an additional trigger for the release of C6 and C7 from PMNs, suggesting a new role for the terminal complement complex (TCC) on target membranes as modulator of PMN functions locally at the site of inflammation." Order ALL the reference details at left...
4.	Melanoma (Melanoma, Malignant) 03/01/1994 - "Targeted neutralization of the complement membrane attack complex inhibitor CD59 on the surface of human melanoma cells." 07/01/1987 - "The efficiency of the membrane attack complex (MAC) in killing M21 melanoma cells was determined varying the molar ratio of cell-bound C9:C8. " 02/01/1993 - "Collectively, these results show that SK-MEL-170 human melanoma cells evade complement-mediated cytolysis despite sufficient activation of early components of the classical complement pathway by p65-mediated rapid degradation of surface-bound C3b, leading to a significant reduction in membrane attack complex formation. " 03/01/1994 - "In the present study we have developed a procedure to simultaneously direct the complement membrane attack complex and neutralize its inhibitor CD59 (protectin) on human melanoma cells in vitro. " 07/01/1987 - "Killing of human melanoma cells by the membrane attack complex of human complement as a function of its molecular composition." Order ALL the reference details at left...
5.	Proteinuria 11/01/1999 - "These studies document for the first time an important role for C6, and therefore C5b-9, in the pathogenesis of nonimmunologic tubulointerstitial injury induced by proteinuria. " 10/01/2005 - "Complement activation leads to assembly of C5b-9 on glomerular epithelial cell (GEC) plasma membranes and is essential for sublethal GEC injury and the onset of proteinuria. " 05/01/2005 - "Targeted inhibition of complement activation by Crry, and of membrane attack complex (MAC) formation by CD59 was equally therapeutic, demonstrating that the MAC plays a key role in proteinuria-induced tubulointerstitial injury. " 02/01/2005 - "Here, we examined whether C5b-9 has a pathogenic role in tubulointerstitial disease in the absence of proteinuria. " 02/01/2005 - "C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Complement System Proteins (Complement)
2.	Proteins (Proteins, Gene)
3.	Antigen-Antibody Complex (Immune Complex)
4.	Complement Membrane Attack Complex (Membrane Attack Complex)
5.	Vitronectin
6.	Monoclonal Antibodies
7.	Antigens
8.	CD59 Antigens
9.	Immunoglobulin G (IgG)
10.	Immunoglobulins (Immunoglobulin)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Transplants (Transplant)
3.	Lasers (Laser)
4.	Cardiopulmonary Bypass (Heart-Lung Bypass)
5.	Angioplasty (Angioplasties)

Best Treatments:
Research Summary Report
on Membranous Glomerulonephritis

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 95 Outcomes
Top 200 Key Drugs and Biologics
Top 29 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>